Sydnexis Inc. is focused on decreasing myopic progression in children. The company offers a novel, stable, and comfortable topical eyedrop used once daily at bedtime, supported by a Phase 3 study.

Sydnexis Inc.

Sydnexis | 1,114 followers on LinkedIn. We focus on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic. | Myopia is the most common eye disease in children and has
experienced a dramatic increase in prevalence over the last 30 years.
Once considered a benign refractive condition, even at low levels,
myopia is now associated with many serious ophthalmic co-
morbidities. The greater myopia severity, the higher the risk of these
ophthalmic co-morbidities later in life.

Zach Scheiner

Vice President, Manufacturing at Sydnexis

Kenneth Laderman, Ph.D.

Sr. Director, Project Management at Sydnexis

Timothy Murphy, MS

Chief Commercial Officer, Sydnexis

Nick Ruth

Sydnexis

At the 2024 ARVO meeting, there were a number of groundbreaking myopia posters and papers. Review of Myopia Management ’s article does a great job of collecting the studies of interest for myopia. Pay close attention to article #20, The Projection of Glaucoma Burden Worldwide in 2060 with Myopia Surge. Truly shocking forecast. https://lnkd.in/e5pvTUNJ #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #glaucoma

Compared with low and moderate myopia, patients with a high degree of myopia experienced impaired quality of life similar to that of patients with keratoconus. #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

Discover the dynamic individuals who power Sydnexis forward. Today we spotlight Kenneth Laderman, Ph.D. Click here to watch the video! https://lnkd.in/gSmD7vB3

Global Myopia Rates in Children and Teens Expected to Surpass 740 Million by 2050. https://lnkd.in/dy3ybvEh #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

National Academies of Sciences, Engineering, and Medicine’s, recently published, Consensus Study Report on Myopia recommends CMS to classify Myopia as a Disease (Recommendation 8-5). https://lnkd.in/eXCBYjFe #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

National Geographic is spotlighting the concerning rise of myopia worldwide. https://lnkd.in/e-jK2AmG #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

Alert! One in Three Children worldwide are now Myopic. https://lnkd.in/d2hmBRFm #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

Post-Myopic Maculopathy: What Is It and How Is It Treated? Preventing moderate-to-severe myopia is vital, to minimize the risk of developing of pathological myopia. Efforts to target myopia awareness and the management of myopia progression in childhood are imperative. Read the article - https://lnkd.in/eZkKUqcx #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy

Do Not wait to begin myopia treatment. Study reinforces the immense importance of starting myopia treatment as soon as possible, because every diopter lost can never be recovered. #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #visionimpairment

The Economic Burden of Vision Impairment is Great. Costs differences, over the lifetime of a patient, are dramatic compared to non-vision impaired individuals. #MyopiaAwareness #childhoodmyopia #myopia #myopiamanagement #myopiacontrol #optometry #optometrist #ophthalmology #ophthalmologist #myopicmaculopathy #EyeCare #FutureVision #eyecarecost #visionimpairment

Euro

CrUX Dataset

CrUX Top 50m

Sr. Director, Project Management

Timothy Murphy

Vice President of Manufacturing

Kenneth Laderman

Vice President Program Management

Linda Gieschen

President

Patrick Johnson

Jeffry Weinhuff

Tyler J. Stowater

Gregory Grunberg

Richard L. Lindstrom

Gregory Ostrow

Advisor and Founder

Chief Business Officer

Jacqueline Johnson

Co-Founder and Chief Operating Officer

Ken Widder

Chief Executive Officer

Chief Commercial Officer

Greater San Diego Area Companies With Fewer Than 50 Employees (Top 10K)

Startups with Female Founders (Top 10K)

United States Early Stage Companies (Top 10K)

United States Manufacturing Companies (Top 10K)

Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.

Bluestem Capital

SC Master Fund

Visionary Venture Fund

Series B - Sydnexis

Venture Round - Sydnexis

Del Mar

California

United States

North America

Perry J. Sternberg Joins Sydnexis as Chief Executive Officer

Nick J. Ruth has been Inducted into the Prestigious Marquis Who's Who Biographical Registry

Olympian Mary Lou Retton Suffers Setback in Battle With Rare ...

Myopia and presbyopia treatment market to grow by USD 7.94 ...

Sydnexis Welcomes Nick Ruth as Chief Commercial Officer

Sydnexis scoops $45M to treat short-sightedness in kids

Santen and Sydnexis partner on childhood myopia treatment SYD-101

Santen, Sydnexis Unite To Vanquish Childhood Myopia

A patented eyedrop formulation undergoing Phase 3 clinical trials for treating progressive myopia in children.

A Phase 3 clinical trial evaluating two dosage strengths of SYD-101 in children aged 3-14 for myopia progression treatment.

news impact assignment basic	general
public peers	general	Nov 19, 2024 5:54 AM	df94dd1c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 5:54 AM	c878de60
crunchbase trigger	general	Nov 19, 2024 5:54 AM	56cf56d5
crunchbase profile	general	Nov 19, 2024 11:45 PM	a97a59a5
li profile	general	Nov 19, 2024 5:54 AM	22d70dd2
translate crunchbase fundingrounds	general	Nov 20, 2024 12:30 AM	67933d66
peers	general	Nov 19, 2024 5:54 AM	dd31c4d1
news basic	general	Nov 19, 2024 5:54 AM	e984d658
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

SYDN

COM:SYDNEXIS

Sydnexis Inc.